Abbott ABT today announced that the U.S. Food and Drug Administration approved the RX ACCULINK® Carotid Stent System for the treatment of patients with carotid artery disease who are at standard risk of adverse events from carotid endarterectomy.
RX ACCULINK was previously indicated for patients at high risk of adverse events from surgery. This expanded indication is supported by the results of the CREST study. RX ACCULINK, used with the RX ACCUNET® Embolic Protection System, represents an important option for standard-risk patients for the treatment of carotid artery disease.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in